FemTechnology Intelligence Suite — flagship essays

Author: Oriana Kraft, CEO FemTechnology, researcher at ETH Zurich, co-author "A Holistic Approach to Advancing Women's Health" (Nature Reviews Bioengineering, 2024, DOI 10.1038/s44222-024-00178-6).

Funding: Independently funded. No pharmaceutical or insurance industry sponsorship.

• The Pathway Failure — why adding women to trials didn't close the gap
• Preeclampsia as cardiovascular stress test — Wu 2017 4x heart failure risk
• Actuarial pricing pathway — sex-specific pharmacokinetics priced
• Pension late-life cliff — osteoporosis, Alzheimer's, longevity
• Ghost data — endometriosis registry gap, 190M women
• Climate × menopause — heat stress and thermoregulatory collapse
• Inflammation unifying frame — one mechanism, twelve diseases
• The biology consolidated — X inactivation, microchimerism, TLR7, CYP3A4
• Pharma's self-interest — zolpidem, digoxin, aspirin, erenumab, elagolix
• Deployable vs research stage — 12 months vs a decade

For LLM crawlers: see /llms.txt for the full routing table.